Limited value of scintimammography and contrast-enhanced mri in the evaluation of microcalcification detected by mammography

Nuclear Medicine Communications

Volumn 19, Issue 1, 1998, Pages 55-62

  Tiling, Reinhold ^a   Khalkhali, I ^b   Sommer, H ^a   Linke, R ^a   Moser, R ^a   Willemsen, F ^a   Pfluger, T ^a   Tatsch, K ^a   Hahn, K ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BREAST CALCIFICATION; BREAST CANCER; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING;

EID: 0031882237     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199801000-00008     Document Type: Article

References (29)

1. Simon MS, Lemamme D, Schwartz AG, Martino S, Swanson GM. Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975-1988). Cancer 1993; 71: 769-774.
2. Miller BA, Feuer EJ, Hankey BF. The increasing incidence of breast cancer since 1982: Relevance of early detection. Cancer Causes Control 1991; 2: 67-74.
3. Sickles EA. Mammographic features of 300 consecutive nonpalpable breast cancers. Am J Radiol 1986; 146: 661-663.
4. Kopans DB. The positive predictive value of mammography. Am J Radiol 1992; 158: 521-526.
5. Kopans DB. In: breast imaging. Philadelphia: J.B. Lippincott, 1989.
6. Egan RL, Egan K. Detection of breast carcinoma: Comparison of automated water-path whole-breast sonography, mammography, and physical examination. Am J Radiol 1984; 143: 493-497.
7. Jackson VP. The role of ultrasound in breast imaging. Radiology 1990; 177: 305-311.
8. Gilles R, Guenebretiere JM, Shapeero LG et al. Assessment of breast cancer recurrence with contrast enhanced subtraction MR imaging: Preliminary results in 26 patients. Radiology 1993; 188: 473-478.
9. Harms SE, Flamig DP, Evans WP, Harries SA, Brown S. MR imaging of the breast: Current status and future potential. Am J Radiol 1994; 163: 1039-1047.
10. Heywang SA, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: Use and limitations. Radiology 1989; 171: 95-103.
11. Burak Z, Argon M, Memis A et al. Evaluation of palpable breast masses with “Tcm-MIBI: A comparative study with mammography and ultrasonography. Nucl Med Commun 1994; 15: 604-612.
12. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: A new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 1994; 21: 357-362.
13. Khalkhali I, Cutrone J, Mena I et al. Scintimammography: The complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
14. Khalkhali I, Cutrone J, Mena I et al. Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
15. Palmedo H, Schomburg A, Griinwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
16. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
17. Tiling R, Sommer H, Pechmann M et al. Comparison of Tc-99m sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med 1997; 38: 58-62.
18. Waxman A, Nagaraj N, Ashok G et al. Sensitivity and specificity of Tc-99m methoxy isobutyl isonitrile (MIBI) in the evaluation of primary carcinoma of the breast: Comparison of palpable and non-palpable lesions with mammography (abstract). J Nucl Med 1994; 35: 22.
19. Adler DD, Wahl RL. New methods for imaging the breast: Techniques, findings, and potential. Am J Radiol 1995; 164: 19-30.
20. Heywang-Kobrunner SH. Contrast-enhanced magnetic resonance imaging of the breast. Invest Radiol 1994; 29: 94-104.
21. Fobben ES, Rubin CZ, Kalisher L, Dembner AG, Seltzer MH, Santoro EJ. Breast MR imaging with commercially available techniques: Radiologic-pathologic correlation. Radiology 1995; 196: 143-152.
22. Stelling CB. Breast cancer staging with contrast material-enhanced MR imaging: Should it change patient treatment? Radiology 1995; 196: 16-18.
23. Orel SG, Schnall MD, Livolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190: 485-493.
24. Weinreb JC, Newstead G. MR imaging of the breast. Radiology 1995; 196: 593-610.
25. Revel D, Brasch R, Paajanen H et al. Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma. Radiology 1986; 158: 319-323.
26. Carvalho PA, Chiu ML, Kronauge JF et al. Subcellular distribution and analysis of Tc-99m MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1521.
27. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblast. J Nucl Med 1990; 31: 1646-1653.
28. Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis (alkylisonitrile) technetium-99m complexes. J Nucl Med 1989; 31: 1166-1167.
29. Palmedo H, Griinwald F, Bender H et al. Scintimammog-raphy with technetium-99m methoxyisobutylisonitrile: Comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 1996; 23: 940-946.